Drug Trial Radar · NCT06109649
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
Last checked: Nov 20, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Oct 11, 2023
Primary completion
Dec 2025
Study completion Jun 2026
Sponsor
- Lead sponsor
- Clinuvel, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.
Conditions
- Vitiligo
Interventions
Afamelanotide and NB-UVB LightDrug
Patients will receive combination of NB-UVB twice weekly and afamelanotide every 3 weeks for 20 weeks.
NB-UVB LightProcedure
Patients will receive NB-UVB light twice per week for 20 weeks. Upon study completion, NB-UVB Light Arm participants will have the opportunity to enroll in an open-label extension phase of the study. In this extension phase, participants will undergo the same evaluations and assessments as the ones performed in the main part of the study under Afamelanotide and NB-UVB Light Arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients achieving T-VASI 50 on the bodyTime frame: From baseline to Day 140
Locations
30 sites in 4 countries. Site status is shown where the registry gives one.
CLINUVEL site
Birmingham, Alabama
CLINUVEL site
Fresno, California
CLINUVEL site
Los Angeles, California
CLINUVEL site
Palo Alto, California
CLINUVEL site
San Diego, California
CLINUVEL Site
Washington D.C., District of Columbia
CLINUVEL site
Miami, Florida
CLINUVEL site
Miramar, Florida
CLINUVEL site
Alpharetta, Georgia
CLINUVEL site
Augusta, Georgia
CLINUVEL site
Chicago, Illinois
CLINUVEL site
Baton Rouge, Louisiana
CLINUVEL site
Detroit, Michigan
CLINUVEL site
Minneapolis, Minnesota
CLINUVEL site
Roseville, Minnesota
CLINUVEL Site
Lee's Summit, Missouri
CLINUVEL site
Rochester, New York
CLINUVEL site
Cleveland, Ohio
CLINUVEL site
Philadelphia, Pennsylvania
CLINUVEL Site
Charleston, South Carolina
CLINUVEL site
Thompson's Station, Tennessee
CLINUVEL Site
Cedar Park, Texas
CLINUVEL site
Dallas, Texas
CLINUVEL site
Tyler, Texas
CLINUVEL site
Charlottesville, Virginia
CLINUVEL site
La Réunion, France
CLINUVEL site
Nice, France
CLINUVEL site
Nairobi, Kenya
CLINUVEL site
London, United Kingdom
CLINUVEL site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.